Skip to main content
. 2022 Jan 5;11(1):113. doi: 10.3390/antiox11010113

Figure 1.

Figure 1

Detection of intracellular ROS levels in CD34+ cells of MF patients. (a) Representative histograms for flow cytometry detection of CM-H2DCFDA staining at 6 h in untreated CD34+ cells of HD, MF(JAK2) and MF(CALR) samples. (b) Dot plot shows the percentages of intracellular ROS assessed in HD and in MF samples, with (red dots) or without (black dots) 6 h of Melittin treatment respectively. The comparison between HD and MF was analyzed using Mann–Whitney U test, while the comparisons between treated and untreated cells were analyzed with Wilcoxon matched-pairs signed rank test. (c) Dot plot shows the percentages of intracellular ROS in the comparison between JAK2- or CALR-mutated MF patients compared to HD, with (red dots) or without (black dots) 6 h Melittin treatment respectively. The comparisons between HD and MF(JAK2) and between HD and MF(CALR) was analyzed with Mann–Whitney U test, while the comparisons between treated and not treated cells were analyzed with Wilcoxon matched-pairs signed rank test. (d) Histogram shows the percentages of intracellular ROS after 6 and 24 h; the statistical test used was Wilcoxon matched-pairs signed rank test. (e) Representative dot plots for flow cytometry detection of Annexin V/PI staining in CD34+ cells of MF(JAK2) and MF(CALR) samples. Data are reported as median with 95% CI (confidence interval). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.